Literature DB >> 24821886

New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma.

Matteo S Carlino1, Vu Kwan2, David K Miller3, Catherine A B Saunders2, Desmond Yip4, Adnan M Nagrial5, Jeanne Tomlinson2, Sean M Grimmond3, Richard A Scolyer6, Richard F Kefford7, Andrew V Biankin8, Georgina V Long9.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24821886     DOI: 10.1200/JCO.2013.51.5783

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

1.  An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses.

Authors:  Neil Vasan; Maria Ignez Braghiroli; Alexander N Shoushtari; Richard Kinh Gian Do; Marcia Edelweiss; Ali Shamseddine; Walid Faraj; Deborah Mukherji; Ali Haydar; Ashwaq Olayan; Fouad Sabatin; Rita Assi; Imane El Dika; Leonard B Saltz; Ghassan K Abou-Alfa; Eileen M O'Reilly
Journal:  J Gastrointest Oncol       Date:  2017-06

2.  Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo.

Authors:  Edward J Hartsough; Curtis H Kugel; Michael J Vido; Adam C Berger; Timothy J Purwin; Allison Goldberg; Michael A Davies; Matthew J Schiewer; Karen E Knudsen; Gideon Bollag; Andrew E Aplin
Journal:  Mol Cancer Ther       Date:  2017-11-13       Impact factor: 6.261

3.  Writing guidelines without a net: ECD.

Authors:  Oussama Abla; Robert Arceci
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

4.  Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition.

Authors:  Britta Diedrich; Kristoffer Tg Rigbolt; Michael Röring; Ricarda Herr; Stephanie Kaeser-Pebernard; Christine Gretzmeier; Robert F Murphy; Tilman Brummer; Jörn Dengjel
Journal:  EMBO J       Date:  2017-01-16       Impact factor: 11.598

Review 5.  Targeting RAS-ERK signalling in cancer: promises and challenges.

Authors:  Ahmed A Samatar; Poulikos I Poulikakos
Journal:  Nat Rev Drug Discov       Date:  2014-12       Impact factor: 84.694

6.  Targeting RAS-mutant cancers: is ERK the key?

Authors:  Meagan B Ryan; Channing J Der; Andrea Wang-Gillam; Adrienne D Cox
Journal:  Trends Cancer       Date:  2015-11-01

Review 7.  BRAF inhibitors: experience in thyroid cancer and general review of toxicity.

Authors:  M E Cabanillas; A Patel; B P Danysh; R Dadu; S Kopetz; G Falchook
Journal:  Horm Cancer       Date:  2014-12-03       Impact factor: 3.869

8.  Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.

Authors:  Ravi K Amaravadi; Kathryn E Hamilton; Xiaohong Ma; Shengfu Piao; Armando Del Portillo; Katherine L Nathanson; Matteo S Carlino; Georgina V Long; Igor Puzanov; Xiaowei Xu; Jennifer J D Morrissette; Kenneth Y Tsai; Keith T Flaherty; Jeffrey A Sosman; Grant R Goodman; Grant A McArthur; Anil K Rustgi; David C Metz; Lynn M Schuchter; Paul B Chapman; Antonia R Sepulveda
Journal:  Clin Cancer Res       Date:  2015-07-22       Impact factor: 12.531

9.  BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.

Authors:  Niuscha Yaktapour; Frank Meiss; Justin Mastroianni; Thorsten Zenz; Hana Andrlova; Nimitha R Mathew; Rainer Claus; Barbara Hutter; Stefan Fröhling; Benedikt Brors; Dietmar Pfeifer; Milena Pantic; Ingrid Bartsch; Timo S Spehl; Philipp T Meyer; Justus Duyster; Katja Zirlik; Tilman Brummer; Robert Zeiser
Journal:  J Clin Invest       Date:  2014-10-20       Impact factor: 14.808

10.  Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.

Authors:  P Dietrich; S Kuphal; T Spruss; C Hellerbrand; A K Bosserhoff
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.